Klaus Witthohn

484 total citations
15 papers, 404 citations indexed

About

Klaus Witthohn is a scholar working on Immunology, Biotechnology and Molecular Biology. According to data from OpenAlex, Klaus Witthohn has authored 15 papers receiving a total of 404 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Immunology, 9 papers in Biotechnology and 6 papers in Molecular Biology. Recurrent topics in Klaus Witthohn's work include Toxin Mechanisms and Immunotoxins (10 papers), Transgenic Plants and Applications (9 papers) and Glycosylation and Glycoproteins Research (3 papers). Klaus Witthohn is often cited by papers focused on Toxin Mechanisms and Immunotoxins (10 papers), Transgenic Plants and Applications (9 papers) and Glycosylation and Glycoproteins Research (3 papers). Klaus Witthohn collaborates with scholars based in Germany, Croatia and Sweden. Klaus Witthohn's co-authors include Martin Langer, Hans Lentzen, Birgit Classen, W. Blaschek, Jürgen Eck, Hartwig Steckel, Holger Zinke, Babette Möckel, Jasna Peter‐Katalinić and Johannes Müthing and has published in prestigious journals such as Biochemistry, The FASEB Journal and Biochemical and Biophysical Research Communications.

In The Last Decade

Klaus Witthohn

15 papers receiving 385 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Klaus Witthohn Germany	11	217	187	117	96	41	15	404
Diana Bachran Germany	14	346 1.6×	203 1.1×	82 0.7×	71 0.7×	16 0.4×	20	577
Felipe V. Pereira Brazil	13	217 1.0×	124 0.7×	41 0.4×	61 0.6×	20 0.5×	18	521
Yi Liang China	15	360 1.7×	119 0.6×	37 0.3×	212 2.2×	8 0.2×	26	619
Huange Zhao China	12	164 0.8×	37 0.2×	50 0.4×	45 0.5×	31 0.8×	26	385
Tito A. Sandoval United States	16	227 1.0×	198 1.1×	23 0.2×	144 1.5×	9 0.2×	23	631
Tong Jin China	14	234 1.1×	48 0.3×	45 0.4×	92 1.0×	16 0.4×	34	504
Tae Kwang Ha South Korea	16	471 2.2×	65 0.3×	53 0.5×	77 0.8×	15 0.4×	23	664
Yoshinori Tsuchiya Japan	10	143 0.7×	82 0.4×	24 0.2×	52 0.5×	9 0.2×	19	407
Stefan Böttger Germany	8	241 1.1×	100 0.5×	32 0.3×	83 0.9×	18 0.4×	12	381
Enge Sudarman Germany	9	141 0.6×	36 0.2×	62 0.5×	115 1.2×	25 0.6×	11	444

Countries citing papers authored by Klaus Witthohn

Since Specialization

Citations

This map shows the geographic impact of Klaus Witthohn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Klaus Witthohn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Klaus Witthohn more than expected).

Fields of papers citing papers by Klaus Witthohn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Klaus Witthohn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Klaus Witthohn. The network helps show where Klaus Witthohn may publish in the future.

Co-authorship network of co-authors of Klaus Witthohn

This figure shows the co-authorship network connecting the top 25 collaborators of Klaus Witthohn. A scholar is included among the top collaborators of Klaus Witthohn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Klaus Witthohn. Klaus Witthohn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Trefzer, Uwe, Ralf Gutzmer, Tabea Wilhelm, et al.. (2015). ITOC2 – 019. An open-label multicenter phase II trial of aviscumine in previously treated patients with unresectable stage IV metastatic melanoma. European Journal of Cancer. 51. S7–S7. 1 indexed citations

Trefzer, Uwe, Ralf Gutzmer, Tabea Wilhelm, et al.. (2014). Treatment of unresectable stage IV metastatic melanoma with aviscumine after anti-neoplastic treatment failure: a phase II, multi-centre study. Journal for ImmunoTherapy of Cancer. 2(1). 27–27. 7 indexed citations

Zwierzina, H., Lothar Bergmann, Heiner Fiebig, et al.. (2011). The preclinical and clinical activity of aviscumine: A potential anticancer drug. European Journal of Cancer. 47(10). 1450–1457. 41 indexed citations

Adler, Michael, Martin Langer, Klaus Witthohn, et al.. (2005). Adaptation and performance of an immuno-PCR assay for the quantification of Aviscumine in patient plasma samples. Journal of Pharmaceutical and Biomedical Analysis. 39(5). 972–982. 12 indexed citations

Schumacher, Udo, Iris Burkholder, Lutz Edler, et al.. (2005). Binding of recombinant mistletoe lectin (aviscumine) to resected human adenocarcinoma of the lung.. PubMed. 25(5). 3303–7. 5 indexed citations

Müthing, Johannes, Iris Meisen, Bernhard Kniep, et al.. (2004). Tumor‐associated CD75s gangliosides and CD75s‐bearing glycoproteins with Neu5Acα2‐6Galβ1‐4GlcNAc residues are receptors for the anticancer drug rViscumin. The FASEB Journal. 19(1). 103–105. 25 indexed citations

Müthing, Johannes, Iris Meisen, Patrick Bulau, et al.. (2004). Mistletoe Lectin I Is a Sialic Acid-Specific Lectin with Strict Preference to Gangliosides and Glycoproteins with Terminal Neu5Acα2−6Galβ1−4GlcNAc Residues. Biochemistry. 43(11). 2996–3007. 54 indexed citations

Steckel, Hartwig, et al.. (2003). Effect of Excipients on the Stability and Aerosol Performance of Nebulized Aviscumine. Journal of Aerosol Medicine. 16(4). 417–432. 7 indexed citations

Steckel, Hartwig, et al.. (2003). Effect of cryoprotectants on the stability and aerosol performance of nebulized aviscumine, a 57-kDa protein. European Journal of Pharmaceutics and Biopharmaceutics. 56(1). 11–21. 11 indexed citations

10.

Adler, Michael, Martin Langer, Klaus Witthohn, et al.. (2003). Detection of rViscumin in plasma samples by immuno-PCR. Biochemical and Biophysical Research Communications. 300(3). 757–763. 40 indexed citations

11.

Steckel, Hartwig, et al.. (2003). The effect of formulation variables on the stability of nebulized aviscumine. International Journal of Pharmaceutics. 257(1-2). 181–194. 21 indexed citations

12.

Lutter, Petra, Helmut E. Meyer, Martin Langer, et al.. (2001). Investigation of charge variants of rViscumin by two-dimensional gel electrophoresis and mass spectrometry. Electrophoresis. 22(14). 2888–2897. 34 indexed citations

13.

Classen, Birgit, Klaus Witthohn, & W. Blaschek. (2000). Characterization of an arabinogalactan-protein isolated from pressed juice of Echinacea purpurea by precipitation with the β-glucosyl Yariv reagent. Carbohydrate Research. 327(4). 497–504. 61 indexed citations

14.

Eck, Jürgen, Martin Langer, Babette Möckel, et al.. (1999). Characterization of recombinant and plant‐derived mistletoe lectin and their B‐chains. European Journal of Biochemistry. 265(2). 788–797. 71 indexed citations

15.

Witthohn, Klaus, et al.. (1993). Analytics of Senna Drugs with Regard to the Toxicologicai Discussion of Anthranoids. Pharmacology. 47(1). 98–109. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact